ResMed Inc Chess Depository Interest
RMD: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| sk | LOCK|dxh< | LOCK|x!%?L>! |
ResMed Earnings: Solid Gross Margin Expansion and US Mask Sales Drive Growth
ResMed's fourth-quarter fiscal 2025 underlying EBIT grew 7% on the third, driven by increased product demand and gross margin expanding 150 basis points to 61% on component cost improvements and a currency tailwind. ResMed guided to gross margins expanding to roughly 62% in fiscal 2026.
